BRUKINSA patients can call the myBeiGene® patient support program to talk to a dedicated nurse: 1-833-BEIGENE (1-833-234-4363)
A diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) can be difficult and overwhelming. That’s why it is important to discuss the benefits and risks of treatment options and responses with your doctor.
In the BRUKINSA trials, 2 types of responses were studied. Progression-free survival (PFS), or the rate at which patients live without their disease worsening, was 1 response and the main purpose of this study. The other response, and a secondary purpose of this study, was overall response rate (ORR), or the percentage of patients in which treatment is working.
Talking to your doctor about these responses can help you find the treatment option that may be right for you.
In a trial comparing BRUKINSA to a combination therapy known as BR, more patients taking BRUKINSA continued responding to treatment with no sign of CLL/SLL worseningThe trial included 589 patients who had never received treatment for their CLL/SLL. 479 patients in the trial who did not have a genetic mutation known as del(17p) received either BRUKINSA or BR, which is a combination of bendamustine (a type of chemotherapy) and rituximab (a targeted therapy). There were also 110 patients with the del(17p) mutation who received BRUKINSA in a separate treatment arm.
*When patients improved, tests showed that their cancer got smaller in size and did not spread.
Patients with the del(17p) mutation responded to treatment with BRUKINSACertain people with CLL/SLL have a genetic mutation called del(17p). Because these patients don’t usually respond well to chemoimmunotherapy, they were studied separately to see how they’d respond to just BRUKINSA.
89
Individual results may vary.
Fewer patients stopped treatment with BRUKINSA because of side effects than those taking BRThis BRUKINSA-only study included CLL/SLL patients, some of whom received BRUKINSA as their first treatment and some of whom received BRUKINSA after receiving a prior treatment.
These results presented are consistent with, but not included in, the FDA-approved prescribing information.
Individual results may vary.
People taking BRUKINSA may experience side effects. In CLL/SLL clinical trials, 8% of previously untreated and 15% of previously treated patients discontinued treatment due to side effects. It’s important to remember that everyone responds to medication differently.
Speak to your doctor about side effects of concern. Most side effects can be managed by your doctor to help you feel better and stay on treatment. Be sure to tell your doctor right away about any new or worsening side effects.
The most common side effects of BRUKINSA include:These are not all the possible side effects of BRUKINSA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
If side effects occur, partnering with your doctor can help you manage any symptoms you may experience and may help ensure you can continue treatment with BRUKINSA.
You will continue to take BRUKINSA for as long as your doctor thinks it is helping you, or for as long as side effects are manageable.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking BRUKINSA with certain other medications may affect how BRUKINSA works and can cause side effects.
These are not all the possible side effects of BRUKINSA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
BRUKINSA is a prescription medicine used to treat adults with:
It is not known if BRUKINSA is safe and effective in children.
Please see full Prescribing Information including Patient Information.